DOI

Not federally scheduled. However, it would likely be considered an analog of DOB, meaning sales for human consumption or possession with intent to ingest could be prosecuted under the Federal Analogue Act. DOI is regularly used in animal and in vitro research, which has been cited as a reason against scheduling.

DOI (4-yodo-2,5-dimetoxianfetamina) is listed in Annex I to Decree 560/2019, as substituted by Decree 122/2026, and is therefore an estupefaciente under article 77 of the Criminal Code. The current Annex I took effect on 3 March 2026. Law 23.737 criminalizes unauthorized production, manufacture, preparation, distribution, storage, transport, commercial dealing, and possession of estupefacientes.

DOI is not separately printed by exact name in the current June 2026 Poisons Standard or Criminal Code Regulations, but its 2,5-dimethoxy-4-iodoamphetamine structure is directly within the Poisons Standard Schedule 9 alkoxyamphetamine class and Customs Schedule 4 item 5A Alkoxyamphetamines. The current Criminal Code Regulations list the corresponding 2C-I phenethylamine in both controlled-drug and border-controlled-drug schedules, and the current Criminal Code Act treats a qualifying analogue of each listed drug as controlled or border controlled. The Act's possession and import/export offences remain subject to their elements and fault rules. Customs regulation 5 imposes a conditional import rule with licence, permission, presentation, timing and quantity requirements and stated exceptions. Schedule 9's prohibited-substance description includes approved research and analytical, teaching or training exceptions, and the Poisons Standard states implementation may vary among States and Territories.

Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal.

DOI is covered as an amphetamine derivative in Annex IVA of the Royal Decree of 6 September 2017. Annex IVA covers derivatives of 1-phenylpropan-2-amine with permitted phenyl-ring substituents including alkoxy groups and halogens, and permits multiple such substitutions; DOI has 2,5-dimethoxy and 4-iodo substitutions. The decree requires a prior activity licence for import, export, transport, manufacture, production, possession, sale, supply, delivery, or acquisition, and restricts that licence to scientific or medical purposes.

Listed as a controlled substance on Portaria SVS/MS nº 344.²¹ Possession, production, and sale are prohibited.

Controlled as of October 12, 2016 under a broad definition covering 2,5-dimethoxyphenethylamine derivatives. This includes most 2C compounds, DOx series, and related phenethylamines.

Since 1 October 2015, the Czech Republic has listed DOI (2,5-dimethoxy-4-iodoamphetamine) in List 4 of Government Regulation No. 463/2013 Coll., on lists of addictive substances. Under the Addictive Substances Act, List 4 substances may be used only for limited research, scientific, or very limited therapeutic purposes specified in a handling permit; handling includes production, storage, supply, purchase, and sale.

Added to the list of Schedule I controlled substances on April 8, 2007, alongside 2C-E, 2C-P, and DOC.

DOI is expressly listed in Anlage II of Germany's Betäubungsmittelgesetz as 2,5-Dimethoxy-4-iodamfetamin. Anlage II contains marketable but non-prescribable narcotics; unlicensed manufacture, trade, import, export, acquisition, and possession are criminal offences under the Act.

DOI is covered by the Schedule 1 provision for substances structurally derived from alpha-methylphenethylamine with alkoxy or halo ring substitutions. Unauthorised possession of a controlled drug is an offence under the Misuse of Drugs Act 1977, and the 2017 Regulations prohibit its production, supply, importation and exportation except as authorised.

Controlled under the Pharmaceutical Affairs Law as a Designated Substance. Possession and sale are prohibited.

Classified as a Schedule I controlled substance under national drug legislation.

Since 1 July 2025, DOI (2,5-dimethoxy-4-iodoamphetamine) falls within the 2-fenethylamine substance group in List IA of the Netherlands' Opiumwet: its phenyl ring and 2-aminoethyl side chain match the statutory scaffold and permitted iodine, methoxy, and methyl substitutions. Article 2a prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, or manufacturing a substance in a List IA group, subject to the statutory exemptions.

Controlled under the catch-all Analogues section in Schedule 3 (Class C) of New Zealand's drug laws, which covers structural analogs of scheduled substances.⁴⁰

Poland's Group I-NPS catch-all covers DOI as a 2-phenylethylamine derivative bearing iodine and alkoxy substituents on the phenyl ring and a methyl substituent on the side chain. The Group I-NPS provision has applied since 21 August 2018. Under the Act on Counteracting Drug Addiction, possession of a new psychoactive substance is punishable by a fine, while possession of a significant quantity can be punished by a fine, restriction of liberty, or imprisonment for up to three years; supplying it for financial or personal benefit is punishable by imprisonment from one to ten years.

DOI is covered by Schedule 2 Part III's homologue provision because it is chemically related to the listed 2,5-dimethoxyamphetamine and incorporates its amphetamine structural fragment. Part III classifies it as an undesirable dependence-producing substance; unauthorised possession, use, manufacture, supply, sale, import, or export is prohibited under the Drugs and Drug Trafficking Act. The current Schedule 2 text has applied since 14 December 2022; contravening the possession or use prohibition carries a maximum of 15 years' imprisonment, while dealing carries a maximum of 25 years.

DOI is listed as a Schedule 3 psychotropic substance in Appendix 3 to the Enforcement Decree of the Narcotics Control Act, effective 7 February 2025. South Korea prohibits possession, ownership, use, management, import, export, manufacture, sale, solicitation or arrangement of sales, and transfer of Article 2(3)(a) psychotropic substances, except with approval from the Ministry of Food and Drug Safety as provided by decree.

Classified as a Schedule I substance as of August 30, 2007, published by the Medical Products Agency in regulation LVFS 2007:10.

Considered a controlled substance as a defined derivative of α-Methylphenethylamine under Verzeichnis E point 130. Legal when used for scientific or industrial purposes.

DOI is prohibited in Turkey with respect to possession, production, supply, and import, although the legal basis is a generic structural class rather than an exact DOI name listing. PubChem identifies DOI; the official 2015/7238 annex covers the 2-phenylethylamine skeleton with the exact substitution types present in DOI (alpha alkyl, methoxy/alkoxy, and iodine/halogen). Law No. 2313 Article 19 supplies the statutory decision mechanism. Article 188 of the official June 2025 Penal Code text supplies the trafficking/import/manufacture penalties and expressly aggravates offences involving amphetamine derivatives; Article 191 separately addresses use-purpose purchase, acceptance, possession, or use. The Law No. 2313 control-decision framework continues in the official 2016 amendment index and latest June 2026 index.

Ukraine places DOI (2,5-dimethoxy-4-iodoamphetamine) in Table I, List No. 2 of the national controlled-substances list; that list is for especially dangerous psychotropic substances whose circulation is prohibited. Resolution No. 1129 of 5 December 2012 added DOI to that list. The statutory regime defines circulation to include production, manufacture, storage, transport, acquisition, sale, import, and export, and permits Table I List No. 2 substances only for the purposes and grounds specified by law.

DOI is a Class A controlled drug under the phenethylamine-derivative provision in Schedule 2 Part I to the Misuse of Drugs Act 1971. The provision covers alpha-methylphenethylamine derivatives with alkoxy and halide ring substitutions, which includes 2,5-dimethoxy-4-iodoamphetamine. Unless authorised under the statutory regime, possession, production, supply, and importation or exportation are offences or prohibited under the Act.

Finland’s Government Decree 1130/2014 places DOI on the list of psychoactive substances prohibited from the consumer market. The restriction prohibits making the substance available to consumers under the Psychoactive Substances Act framework; it is distinct from narcotics scheduling.

DOI is listed in the Narkotikalisten as 2,5-dimetoksy-4-jodamfetamin. Under the Medicines Act, its manufacture, import, wholesale and retail supply require express authorization; sale, dispensing and dispatch are limited to medical and scientific use. Possession and use without lawful access are prohibited.

DOI (2,5-dimetoxi-4-yodoanfetamina) is not included in the current Lista I of Annex 1 to Real Decreto 2829/1977, Spain's controlled psychotropic schedule. The annex separately lists the related 2C-I (2,5-dimetoxi-4-iodofenetilamina) and DOC (2,5-dimetoxi-4-cloroanfetamina), but not DOI; the decree subjects only the substances referred to in Lists I–IV and their preparations to its controls.